HomePeptide SynthesisBiotinylation Reagents

Biotinylation Reagents

Biotin-labeled peptides have many important applications in immunology and histochemistry, such as affinity purification1 and FRET-based flow cytometry2, solid-phase immunoassays3, and receptor localization4, that exploit the high affinity of streptavidin and avidin for biotin.

Incorporation of the biotin label is best carried out during solid phase synthesis of the peptide ligand, with the optimum location for the biotin label dependent on the nature of the application.

Biotin NovaTag™ resin

Biotin NovaTag™ resin

Fmoc-PEG Biotin NovaTag™ resin

Fmoc-PEG Biotin NovaTag

The biotin label is most frequently located directly on the N-terminal group of the peptide, often without any regard to how this may affect peptide-target interactions, biotin-avidin binding, and the solubility properties of the resultant peptide. In many instances the products are poorly soluble and have little biological activity and poor affinity for biotin. Problems can also arise during the synthesis of such N-terminally biotinylated peptides due to the poor solubility and reactivity of many of the reagents used for biotin introduction.

Novabiochem®’s biotin-loaded NovaTag™ resins provide a simple and elegant solution to these problems5-9. Using these resins, biotinylated peptides are obtained directly following TFA cleavage, without the need for any additional biotinylation steps. Resins incorporate either an ethylenediamine or a 15 atom PEG spacer between the peptide and biotin to reduce steric hindrance.

The use of Fmoc-PEG Biotin NovaTag™ resin is particularly advantageous because not only does the hydrophilic PEG chain confer better solubility to the peptide biotin conjugate, but its extended conformation leads to better avidin binding which can dramatically improve assay sensitivity as demonstrated in Figure 2. Since the biotin is an integral part of the linker, its presence in every peptide chain is assured from the outset.

Fmoc-PEG Biotin NovaTag™ resin can be used directly in an automated synthesizer in the same manner as Rink amide resin. The Fmoc group is removed with 20% piperidine and the peptide assembled on the support using standard protocols. Cleavage from the resin using standard TFA cocktails affords the C-terminally labeled biotinylated peptide.

Biotinylated peptide design

When designing biotinylated peptides for use in assays, two of the most important considerations are the position of the biotin moiety and the nature of the spacer group between the peptide and biotin. These can profoundly affect the strength of peptide-protein and biotin-avidin interactions and consequently the sensitivity of the assay. The importance of correct peptide presentation is illustrated in the following examples taken from developmental work on protein-binding and kinase assays carried out at Merck KGaA, Darmstadt, Germany10.

AlphaScreen™ protein-binding assay

The peptide-protein binding assay was conducted using the AlphaScreen™ technology as shown in Figure 1. N- and C-terminally biotin-labeled versions of the native peptide ligand immobilized on streptavidin-coated donor beads were screened against acceptor beads loaded with target protein. Only the peptide which was C-terminally labeled with PEG-biotin had acceptable solubility in the test buffer and showed significant levels of protein binding (Figure 2).

Principles of the protein-peptide binding AlphaScreen™ assay

Figure 1.Principles of the protein-peptide binding AlphaScreen™ assay.

AlphaScreen protein-binding assay

Figure 2.AlphaScreen protein-binding assay. Peptide 1: N-biotin-XXXXX-NH2; peptide 2: H-XXXXX-NHCH2CH2NH-biotin; peptide 3: H-XXXXX-NH-PEG-NH-biotin10

Kinase bind assay

N- and C-terminally biotin-labeled versions of a kinase substrate were evaluated in the assay shown in Figure 3. Peptides that were C-terminally labeled with biotin were found to give better reponses than those that were labeled on the N-terminus, whilst inclusion of a PEG spacer between the peptide and biotin appeared to have little effect (Figure 4).

Principles of the kinase assay

Figure 3.Principles of the kinase assay

Kinase assay












For coupling of biotin to amines on the solid phase the use of Biotin-ONp is strongly recommended11. The solubility of this reagent in DMF or NMP is much greater than that of Biotin-OSu (Table 1), and it couples with amines much more rapidly (Figure 5): typically, in 40 min as opposed to 12 h for Biotin-OSu.

Table 1.Properties of base resins
Coupling rate of Biotin-OSu and Biotin-ONp

Figure 5.Coupling rate of Biotin-OSu and Biotin-ONp to H-Asp(OtBu)-Glu(OtBu)-Val-Glu(OtBu)-Wang resin.

Alternatively, preformed derivatives such as Fmoc-Lys(biotin)-OH, Fmoc-Lys(biotinyl-e-aminocaproyl)-OH, Fmoc-Asp(biotinyl-PEG)-OH and Fmoc-Glu(biotinyl-PEG)-OH can be used to introduce biotin at a precise location within a peptide chain. The use of Fmoc-Glu(biotinyl-PEG)-OH is particularly recommended. In contrast to the other derivatives, it possesses good solubility in DMF (Fmoc-Glu(biotinyl-PEG)-OH, 0.5 mmole/ml; Fmoc-Lys(biotin)-OH, <0.05 mole/ml; Fmoc-Lys(biotinyl-e-aminocaproyl)-OH, <0.05 mmole/ml). Furthermore, the PEG chain improves the solubility of the product biotinylated peptide [1b] and helps reduce steric hindrance between peptide and biotin, leading to better avidin binding. It is recommended that NMP or NMP/DMSO be used as the solvents for Fmoc-Lys(biotin)-OH and Fmoc-Lys(biotinyl-e-aminocaproyl)-OH. For convenience, Fmoc-Lys(biotinyl-e-aminocaproyl)-OH pre-loaded onto NovaSyn® TGR A resin is available.

N-Biotinyl-NH-PEG2-COOH and N-Biotinyl-NH-PEG11-COOH offer the same benefits as Fmoc-Glu(biotinyl-PEG)-OH and are ideal for incorporation of biotin-PEG at the N-terminus of a peptide. The long 40 atom spacer in the latter has a marked effect on peptide solubility compared to that of Glu(biotinyl-PEG) or N-biotinyl-NH-PEG.



Hofmann K, Kiso Y. 1976. An approach to the targeted attachment of peptides and proteins to solid supports.. Proceedings of the National Academy of Sciences. 73(10):3516-3518.
T. Buranda, . (1999). et al. Cytometry, . 37, 21.
Sélo I, Négroni L, Créminon C, Grassi J, Wal J. 1996. Preferential labeling of ?-amino N-terminal groups in peptides by biotin: application to the detection of specific anti-peptide antibodies by enzyme immunoassays. Journal of Immunological Methods. 199(2):127-138.
HOWL J, WANG X, KIRK CJ, WHEATLEY M. 1993. Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor. Eur J Biochem. 213(2):711-719.
Kumar V, Aldrich JV. 2003. A Solid-Phase Synthetic Strategy for Labeled Peptides:? Synthesis of a Biotinylated Derivative of the ? Opioid Receptor Antagonist TIPP (Tyr-Tic-Phe-Phe-OH). Org. Lett.. 5(5):613-616.
Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L. 2009. Perturbation of Estrogen Receptor ? Localization with Synthetic Nona-Arginine LXXLL-Peptide Coactivator Binding Inhibitors. Chemistry & Biology. 16(7):702-711.
Parisot J, Kurz K, Hilbrig F, Freitag R. 2009. Use of azobenzene amino acids as photo-responsive conformational switches to regulate antibody-antigen interaction. J. Sep. Science. 32(10):1613-1624.
Shiryaev S, Kozlov I, Ratnikov B, Smith J, Lebl M, Strongin A. 2007. Cleavage preference distinguishes the two-component NS2B?NS3 serine proteinases of Dengue and West Nile viruses. 401(3):743-752.
Millward SW, Fiacco S, Austin RJ, Roberts RW. 2007. Design of Cyclic Peptides That Bind Protein Surfaces with Antibody-Like Affinity. ACS Chem. Biol.. 2(9):625-634.
O. Pöschke. unpublished results..
Baumeister B, Beythien J, Ryf J, Schneeberger P, White PD. 2005. Evaluation of Biotin-OSu and Biotin-ONp in the Solid Phase Biotinylation of Peptides. Int J Pept Res Ther. 11(2):139-141.
B. Baumeister, et al.. 2003. Biopolymers. 71(339):